~~<i id='BD566078F3'><strike id='BD566078F3'><tt id='BD566078F3'><pre id='BD566078F3'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：focus 2025-09-28 05:14:53 Page View：94

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： A solution to the after
Next article： Affirmative action in medical school literally saved lives

comprehensive

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

2:51AnaerialviewshowsawildfireinMauiCounty,Hawaii,August8,2023inthisscreengrabobtainedfromasocialmed

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

AdobeHospitals,pharmacies,andotherhealthcareprovidersaregettingstuckinaninsuranceprocessinglogjamaft